Abstract
Purpose: To investigate vision-related quality of life in patients referred to the Italian Retina Services for intravitreal ranibizumab treatment for choroidal neovascularization due to pathologic myopia. Design: Post hoc analysis of a multicenter, interventional phase IIIb study (OLIMPIC). Methods: Patients with either previously untreated (naïve) or treated choroidal neovascularization due to pathologic myopia were enrolled. Vision-related quality of life was measured using the Italian version of the Impact of Vision Impairment Questionnaire with scores from 0 (no impact) to 5 (severe impact). Burden of illness data were collected regarding income, and personal and public resource use. Results: In the 200 included subjects, mean best-corrected visual acuity in the better eye was 68.3 Early Treatment Diabetic Retinopathy Study letters (standard deviation: 15.2) compared with 42.5 Early Treatment Diabetic Retinopathy Study letters (standard deviation: 23.3) in the worse eye. The proportion of better eyes affected by choroidal neovascularization was 147/200 (73.5%). In multivariable analyses, lower better eye, but not worse eye, best-corrected visual acuity was associated with lower vision-related quality of life (per 10 fewer letters, beta: + 0.17, p < 0.001). An annual income below 20,000 euros was also associated with lower vision-related quality of life (beta: + 0.38; standard error: 0.13, p = 0.004). Moreover, in univariate analyses, increasing income level was linearly associated with better presenting best-corrected visual acuity in the better eye (p < 0.003), with a difference of 15 Early Treatment Diabetic Retinopathy Study letters for patient income <20,000 euros compared with >70,000 euros. Conclusion: Italian patients with myopic choroidal neovascularization and a low income presented with lower better-eye best-corrected visual acuity and lower vision-related quality of life compared with those with a higher income. Future research should investigate disease awareness and candidacy issues that may influence the quality of life of patients.
| Original language | English |
|---|---|
| Pages (from-to) | 1069-1075 |
| Number of pages | 7 |
| Journal | European Journal of Ophthalmology |
| Volume | 30 |
| Issue number | 5 |
| Early online date | 06 Jun 2019 |
| DOIs | |
| Publication status | Published - 01 Sept 2020 |
| Externally published | Yes |
Bibliographical note
Funding Information:This analysis was supported by an unrestricted grant by Novartis Spa, Italy. The authors received raw study data, conducted analyses and drafted the manuscript. Novartis agreed on the statistical analysis plan and accessed the manuscript before submission but no change to the intended objectives and results, other than text editing, was provided to the authors. Therefore, this manuscript is solely the result of the authors? work. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The Department of Translational Surgery and Medicine of the University of Florence received financial support for conducting this study. The research for this paper was financially supported by Italian Ministry of Health and Fondazione Roma. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
Publisher Copyright:
© The Author(s) 2019.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
Keywords
- myopia
- myopic choroidal neovascularization
- Quality of life
ASJC Scopus subject areas
- Ophthalmology
